Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00321516 · ClinicalTrials.gov registry record · Phase 1
Drug-drug Interaction Study of Aripiprazole and Lamotrigine in Patients With Bipolar Type I Disorder
A Phase 1 study of Bipolar Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 4
- Study locations
NCT00321516: Completed Phase 1 study of Bipolar Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization.
NCT00321516 is a Phase 1 study of Bipolar Disorder that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 20 participants, below the 333-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00321516, a Phase 1 study of Bipolar Disorder, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this clinical research study is to learn if aripiprazole has a drug-drug interaction with lamotrigine.
Conditions Studied
Interventions
- DRUG aripiprazole
Study Locations (4)
Texas
- Local Institution - Austin
- Local Institution - Bellaire
- Local Institution - Desota
Pennsylvania
- Local Institution - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-07 |
| Est. Completion | 2007-02 |
| Phase | Phase 1 |
What the finished NCT00321516 record still lists
NCT00321516 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 333-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Bipolar Disorder appearing as the primary indexed condition, and to 1 intervention - of which aripiprazole is the first listed.
NCT00321516 reports a single indexed study location in Texas, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00321516 about?
NCT00321516 is a clinical study titled "Drug-drug Interaction Study of Aripiprazole and Lamotrigine in Patients With Bipolar Type I Disorder". The purpose of this clinical research study is to learn if aripiprazole has a drug-drug interaction with lamotrigine.
What is the current status of trial NCT00321516?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2006-07. Estimated completion is 2007-02.
What conditions does trial NCT00321516 study?
This clinical trial studies the following conditions: Bipolar Disorder.
What interventions are being tested in trial NCT00321516?
The interventions under investigation include: aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00321516?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00321516 being conducted?
This trial has 4 study locations across Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00321516's enrollment target sits among peer trials
20 154th of 162 higher than 6 of 162 other Bipolar Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bipolar Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Effectiveness of Family-Focused Psychoeducation in Treating Adolescents With Bipolar Disorder
COMPLETED · Phase 1
-
Valproate Efficacy in Cocaine-Bipolar Comorbidity
COMPLETED · Phase 1
-
Taking Action for College Students
RECRUITING · NA
-
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
RECRUITING · Phase 3
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia